CD274 and neoplasm: Although clinical trials are underway to investigate the efficacy of targeting the PD-1/PD-L1 axis in BrCa, the combination of immune checkpoint inhibition and other immunotherapeutic strategies, such as RV, to produce a more robust anti-tumor immune response is of interest.